Background Prostate cancer is a major public health problem with considerable uncertainties about the eff ectiveness of population screening and treatment options. We report the study design, participant sociodemographic and clinical characteristics, and the initial results of the testing and diagnostic phase of the Prostate testing for cancer and Treatment (ProtecT) trial, which aims to investigate the eff ectiveness of treatments for localised prostate cancer.
Introduction
Prostate cancer is the most frequently diagnosed cancer in men in developed countries, with an estimated 241 740 new cases and 28 171 deaths caused by the disease every year in the USA alone. 1 In the UK, it is the second most common cause of cancer deaths in men (13%) with 41 763 new cases diagnosed and 10 793 deaths caused by the disease in 2011. 2 The disease can be detected early by prostate-specifi c antigen (PSA) measurement followed by prostate biopsy. However, most screen-detected cancers are at low risk of progression, and potential harm could be caused by unnecessary diagnosis and treatment.
The publication of two population-based randomised controlled trials 3, 4 of screening has not resolved this dilemma. The European Randomized Study of Screening for Prostate Cancer (ERSPC) 3 reported a clear but relatively small disease-specifi c survival benefi t from screening compared with no active intervention at 8 years' and 13 years' follow-up, with a larger eff ect reported in a smaller Scandinavian cohort at 14 years after diagnosis. 4 By contrast, the US-based Prostate, Lung, Colorectal, and Ovarian (PLCO) trial 5 reported no benefi t from screening with a similar length of follow-up, but was limited by substantial contamination from previous PSA testing in the control group in more than 50% of the unscreened men.
Most men diagnosed with PSA-detected prostate cancer tend to undergo radical treatment. Active monitoring or surveillance with deferred radical treatment has been advocated to avoid immediate, potentially unnecessary, intervention. However, absence of evidence about optimal protocols precludes a clear defi nition of safety for this option. Two randomised trials 6, 7 have compared radical surgery with passive observation (so-called watchful waiting). The US-based Prostate cancer Intervention Versus Observation Trial (PIVOT) 6 reported no overall mortality benefi t from surgery in patients with PSA-detected cancer, whereas the Scandinavian Prostate Cancer Group 4 trial (SPCG-4) 7 showed a clear diseasespecifi c and overall survival benefi t for surgery in patients presenting clinically, as well as a reduction in progression to metastatic disease.
The Prostate testing for cancer and Treatment (ProtecT) randomised trial was designed to assess the eff ectiveness and cost-eff ectiveness of active monitoring (a surveillance protocol), external beam conformal radiotherapy with neoadjuvant androgen suppression, and radical prostatectomy for men with PSA-detected clinically localised prostate cancer. Analysis of the primary outcome of disease-specifi c mortality is scheduled for 2016, at 10 years' median follow-up. Here we present the trial design, the initial results of the PSA testing and diagnostic phase, and the clinical and sociodemographic characteristics of the randomly assigned participants.
Methods

Study design and participants
The ProtecT trial was designed in the late 1990s and early 2000s to compare the major conventional treatments for patients with clinically localised prostate cancer detected through population-based PSA testing. The three treatments were radical prostatectomy, external beam three-dimensional (3D) conformal radiotherapy, and active monitoring.
Recruitment was undertaken in two stages: a feasibility pilot in three English cities (in 24 primary care centres linked to three university hospitals) from June, 1999, to September, 2001 (ISRCTN08435261), and the main trial from October, 2001, to January, 2009, in nine cities (seven in England, one in Scotland, and one in Wales). 8 Also in 2001, the CAP trial (Cluster randomised triAl of PSA testing for Prostate cancer; ISRCTN92187251) commenced, which is an extension to the ProtecT trial. The CAP trial randomly assigned primary care centres to undertake either the ProtecT trial or standard UK National Health Service (NHS) management (no routine PSA testing; fi gure 1), to assess population-based screening in addition to treatment eff ectiveness of clinically localised disease identifi ed in ProtecT. 9 Further details of the CAP trial design and randomisation have been published previously. 10 A written invitation was sent by 337 primary care centres assigned to undertake the ProtecT trial to registered men aged 50-69 years, excluding those with a previous malignancy (apart from skin cancer), renal transplant or on renal dialysis, major cardiovascular or respiratory comorbidities, bilateral hip replacement, or an estimated life expectancy of less 10 years. Men who responded received a ProtecT patient information sheet and an appointment with a specialist nurse who explained the complexities of PSA testing, assessed trial eligibility, and sought written informed consent. Previous PSA test results were checked in the medical records but were not an exclusion criterion. On postal receipt of a second written consent form, total PSA was analysed at site laboratories. Laboratories were audited by the NHS External Quality Assessment Service. Participants with a PSA concentration of at least 3·0 µg/L were invited to attend secondary care centres within the nine participating cities for a physical and digital rectal examination and standardised ten-core transrectalultrasound-guided prostate biopsies. Participants with an initial PSA concentration at least 20·0 µg/L at diagnosis were excluded because of the high likelihood that they had more advanced cancer.
Patients were staged using a combination of digital rectal examination, PSA concentration, transrectal ultrasound-guided biopsies, and isotope bone scanning (if PSA was ≥10 µg/L). MRI was used for staging at the discretion of individual investigators, because this imaging technique was not available in all centres during the recruitment period. Men diagnosed with clinically localised prostate cancer and deemed fi t for radical treatment received a ProtecT treatment patient information sheet, and were subsequently invited to discuss randomisation with the specialist nurses. Men with a PSA concentration of 10 µg/L or higher or a Gleason score of greater than 7 points underwent an isotope bone scan to exclude metastatic disease. Men initially diagnosed with benign biopsy samples, or locally advanced or advanced prostate cancer, were managed within the NHS and excluded from the trial. Men with a benign fi rst biopsy sample and a free-to-total PSA ratio below 11%, or atypical small acinar proliferation or high-grade prostatic intraepithelial neoplasia, were off ered further biopsies; if these repeat biopsy samples were benign, these men were managed in primary care and excluded from the trial. No further trial follow-up occurred after the one round of PSA testing or identifi cation of cancers after referral to the NHS.
Approval was obtained from the UK Trent Multicentre Research Ethics Committee (01/4/025). Histopathologists at each site reported pathology fi ndings on standardised forms and participated in trial quality control processes and those of the NHS Uropathology External Quality Assessment Scheme. The trial steering committee (seven independent members and chair) reviewed trial progress every year. Study training programmes and on-site monitoring visits were used to standardise trial conduct.
11,12
Randomisation and masking
Men discussed treatment options with the specialist nurses, and if they agreed to the three-group randomisation (1:1:1), the nurse telephoned a central system in the Bristol trials' offi ce (Bristol, UK) and logged participant details. Allocations were computer-generated as required for each participant, originally using Microsoft Excel functions, and subsequently in C++, stratifi ed by site with stochastic minimisation to improve the balance across the groups in relation to age at primary care patient identifi cation date, Gleason sum score (<7, 7, or 8-10 points) and mean of baseline and fi rst biopsy PSA results (<6·0, 6·0-9·9, or >9·9 µg/L). The allocation was revealed after the entry of participant details, and then given to the participant by the nurse. Clinicians and participants were not masked to group assignment. Eligible participants were off ered the choice of a two-group randomisation (radical prostatectomy or radiotherapy), or a three-group randomisation (with the addition of active monitoring to the two treatment groups). In 2003, the independent data monitoring committee (DMC) terminated the two-group option because of limited uptake, and the only option for participants who consented was the three-group randomisation throughout the remaining period of recruitment. Men who declined randomisation were off ered identical follow-up and formed a comprehensive cohort within the study design.
Procedures
Participant sociodemographic characteristics, family history of cancer, and previous PSA tests were obtained at recruitment. Clinical management after diagnosis was standardised in the trial protocol using study groupspecifi c pathways. In all treatment groups, androgen deprivation therapy was off ered when serum PSA reached a concentration of 20 µg/L, or less if indicated. Imaging of the skeleton was recommended if serum PSA reached 10 µg/L, using isotope bone scintigraphy, plain radiographs, and MRI as necessary.
In patients randomly assigned to active monitoring, the protocol aim was to avoid immediate radical treatment while assessing the disease over time, with radical treatment off ered if disease progression was evident. PSA concentrations were measured and reviewed every 3 months in the fi rst year and twice yearly thereafter (frequency was changed as indicated). The specialist nurses also met with participants yearly to assess their overall health, and discuss graphical displays of PSA results and any concerns raised, overseen by each centre's local clinical investigator. Changes in PSA concentrations were assessed at each visit, and a rise of at least 50% during the previous 12 months triggered repeat testing within 6-9 weeks. If the PSA concentrations were persistently raised, or the patient had any other concerns, a review appointment was made with the centre urologist for discussion of further tests including re-biopsy and all relevant management options.
In patients randomly assigned to receive external beam 3D conformal radiotherapy, neoadjuvant androgen suppression was given for 3-6 months before and concomitantly with 3D-conformal radiotherapy delivered at 74 Gy in 37 fractions. 13 Quality assurance followed the RT01 trial procedures. 14, 15 PSA concentrations were measured every 6 months for the fi rst year and then yearly. The study oncologist held a review appointment with participants if the PSA concentrations rose by at least 2·0 µg/L post-nadir or concerns were raised about disease progression. 16 Management options were discussed, including continued monitoring, further tests, salvage, radical, or palliative treatments as indicated.
In patients randomly assigned to receive radical prostatectomy, the predominant approach was open retropubic radical prostatectomy with individual-level quality assurance according to minimum standards. 17 Participants with a baseline PSA concen tration of at least 10 µg/L or a biopsy Gleason score of at least 7 points received bilateral lymph adenectomy. Postoperatively, PSA concentrations were measured every 3 months for the fi rst year, every 6 months for 2 years, and then yearly. Adjuvant radiotherapy was discussed and off ered to patients with positive surgical margins or extracapsular disease. The centre urologist held a review appointment with participants if their postoperative PSA concentrations reached 0·2 µg/L or higher to discuss adjuvant radiotherapy.
A linked translational study obtained biological specimens and epidemiological data. 
Outcomes
Outcome measures were selected for relevance to patients and health-care providers. The primary outcome was defi ned as defi nite or probable prostate cancer mortality, including intervention-related deaths, at a median of 10 years' follow-up. Participants were linked to the NHS national registry to obtain vital status information, with the information updated quarterly. The process used to assess cause of death was adapted from the PLCO algorithm 5 and ERSPC process 3 and then combined to assess deaths in both the CAP and ProtecT studies. The medical records of deceased participants were summarised by trained CAP researchers, anonymised, and reviewed by an indepen dent endpoint committee who were masked to ProtecT and CAP trial 10 assignments (fi gure 1). Secondary outcomes include overall mortality (taken from death certifi cates), and incidence of metastases, local disease progression, treatment complications, and resource use for the cost-eff ectiveness analysis (recorded on case report forms by specialist nurses every year from medical records and participant information [18] [19] [20] [21] [22] [23] [24] [25] These validated questionnaires were completed at recruitment, at fi rst biopsy, 6 months after randomisation, and yearly thereafter for at least 10 years. Qualitative interviews investigated participants' experiences of treatments and outcomes. A full list of all prespecifi ed outcomes can be found in our study protocol.
Statistical analysis
Before the start of the trial, a sample-size target of 1434 randomly assigned men (478 in each group) was identifi ed as suffi cient to estimate the absolute diff erence in mortality probability between two treatment groups with a 95% CI of ±0·045, on the basis of an assumed mortality rate of 15%, consistent with prostate cancerspecifi c mortality in men aged 55-69 years with clinically detected disease managed conservatively at that time and a diff erence that would be deemed clinically signifi cant by the NHS. The pilot study recruitment data were used to calculate the number of sites and duration of recruitment needed to meet the sample size target. However, more recent data 10 suggested that diseasespecifi c mortality with non-radical treatment was likely to be closer to 10% at 10 years, because of improvements in disease management. As a result, the DMC advised in 2008 that recruitment should continue to the planned end date, with 1590 men (530 per group) expected to be randomly allocated by that point. This sample size would enable a 46% reduction in prostate cancer mortality to be detected with 80% power at a 5% signifi cance level for a pairwise comparison of a radical treatment with active monitoring. This calculation assumes a 10% prostate cancer-specifi c mortality at 10 years with active monitoring, and hence a 5·4% risk with radical treatment-an absolute diff erence very similar to the margin of error specifi ed in the fi rst calculation. These sample size targets are based on diff erences in and ratios of risk rather than the hazard ratios planned for the primary analysis, because the resulting calculations are simpler and more fl exible. When a high survival rate is expected, calculations based on risk ratios will be a close approximation to those based on hazard ratios. The primary analyses will be done on an intention-to-treat basis comparing treatment groups as allocated. When a median of 10 years of follow-up has accumulated (November, 2015), the primary outcome measure of prostate cancer mortality will be compared between treatment groups using a survival analysis (Cox proportional hazards regression model) adjusted for stratifi cation and minimisation variables. The estimated relative treatment eff ect for each pairwise comparison of treatments will be captured as a hazard ratio, and presented with a 95% CI. Hazard ratios are interpreted in the same way as rate ratios; the advantage of hazard ratios and Cox's proportional hazards model for this study is the accommodation of variation in the underlying rate of prostate cancer mortality during follow-up. Pairwise signifi cance tests will only be done if a test of an equal 10-year disease-specifi c mortality risk across all three groups yields a p value of less than 0·05. 26 This approach will be used for event-based secondary outcomes-ie, grouped analyses of defi nite, probable, or possible prostate cancer, all-cause mortality, and metastatic disease.
Pairwise comparisons of symptom burden will use multilevel models for repeated measures to estimate the average treatment eff ect over the median 10-year followup. Further analyses will investigate the relative burden between treatment groups over time. Prespecifi ed subgroup analyses will investigate whether treatment eff ectiveness in the reduction of prostate cancer-specifi c mortality is modifi ed by baseline clinical stage, Gleason grade, age, or PSA concentration using stratifi ed analyses for descriptive statistics and by formally including interaction terms in the relevant regression models. Secondary analyses will estimate the effi cacy of radical treatment versus active monitoring in the reduction of prostate cancer mortality in individuals who complied with their allocated treatment, by using a method to derive an unbiased estimate in parallel with the per-protocol analysis originally specifi ed in the trial protocol. 27, 28 An analysis of primary and secondary outcome measures by trial group is reported yearly to the DMC. The DMC recommends changes to the trial steering committee if clear evidence (of the order of p<0·001) of a positive or negative balance of risks and benefi ts emerges for one intervention in comparison with the others.
Data from the recruitment, diagnostic, and randomisation phases are presented, and categorisation of continuous variables is either based on clinical thresholds (eg, for PSA) or the aim of equal group sizes (other measures). Resident area-based material and social deprivation scores (the proportion of people living in an area of material deprivation) were derived using Lower Super Output Areas, each equating to around 1500 residents for England, Scotland, and Wales separately.
Analyses were done with STATA version 10. This study is registered as an International Standard Randomized Controlled Trial, number ISRCTN20141297, and with ClinicalTrials.gov, number NCT02044172.
Role of the funding source
The funder had no role in the design or conduct of the study; in collection, management, analysis, or interpretation of the data; or preparation, review, or approval of the report. JAL, FCH, JLD, and DEN had full access to all the data for this analysis (full outcome data will become accessible to them from Nov 15, 2015) and had fi nal responsibility for the decision to submit for publication.
Results
Between Oct 1, 2001, and Jan 20, 2009, 228 966 men were invited to participate in the ProtecT study, of whom 122 502 (54%) responded, although 5954 (5%) of respondents declined to participate and 16 104 (13%) did not attend the appointment with the specialist nurse (fi gure 2). Of the 100 444 (44%) men who did attend, 82 429 (82%) were eligible and agreed to enrol. Of the men who attended their appointment, 10 350 (10%) did not enrol or return their second consent form and 7665 (8%) were deemed ineligible.
73 538 (89%) of the 82 429 recruited participants had a PSA concentration that was below the biopsy cutoff point. Only 279 (<1%) had PSA concentrations of 20 µg/L or higher and were referred for further assessment outside the trial. Of the men tested, 8566 (10%) were referred for biopsies, with high levels of uptake (7414 [87%]). The remainder (1152 [13%]) did not receive biopsies because they either opted to receive monitoring in primary care, or had comorbidities that precluded biopsies. Further Data are median (range) or number (%), unless otherwise indicated. Results are from one round of PSA testing. PSA=prostate-specifi c antigen. *Ineligible participants were excluded (for 46 patients the PSA result was not available and 279 had a PSA concentration of ≥20 µg/L). †129 men were 49 years of age when the primary care list was generated, 120 of whom were 50 years old by recruitment; 25 men were 70 years or older at generation of the primary care list, of whom four were 71 years of age and one was 72 years of age; at the time of recruitment, all men who were enrolled fi tted the stated inclusion criteria as per protocol. ‡p value is a result of the comparison between white ethnic origin and all other ethic origins. §Based on resident area-based material and social deprivation scores-eg, percentage of social housing. biopsies were off ered to the 2357 (32%) men without a defi nitive diagnosis; 1563 (66%) of those off ered underwent the repeat procedure, with a further 322 (14%) receiving a repeat biopsy after advice from a urologist. 2896 men were diagnosed with prostate cancer (4% of those recruited; 39% of those who had a biopsy). 2478 (86%) men with prostate cancer were diagnosed at initial biopsy with 418 (14%) diagnosed after repeat biopsies. 2417 (83%) of the men diagnosed with prostate cancer had clinically localised prostate cancer and were eligible for randomisation. Additionally, of men with a positive biopsy result, 270 (9%) were ineligible for randomisation because they had locally advanced, advanced, or metastatic disease, and 209 (7%) were excluded because of comorbidity.
Predominantly, recruited ProtecT participants were white and married or living with a partner, and 4082 (5%) reported a family history of prostate cancer (table 1).
Median age was 58 years (range 50-69) in the total cohort, with slightly more men younger than 60 years recruited than older men (table 2), and 11 011 (13%) men had received a previous PSA test. A positive relation was noted between a raised PSA concentration, increased age, and receipt of biopsy. The proportions of patients who underwent biopsy were similar between all age groups (table 2). The relation between higher PSA concentrations and prostate cancer diagnosis was unchanged by adjustment for age, whereas the relation between the proportion of recruited patients diagnosed with prostate cancer and increased age was attenuated by adjustment for PSA concentration (unadjusted odds ratio [OR] data not shown; table 2). Ethnic origin, married or partnership status, and extent of material deprivation did not diff er between participants diagnosed with cancer and those without cancer (table 1) .
2417 men recruited to the main ProtecT trial were eligible, as were 247 from the feasibility pilot phase. 8 1643 (62%) of these eligible patients agreed to randomisation (fi gure 3). The median age of all randomly assigned participants was 62 years (range 50-69) with a median PSA of 4·6 µg/L (range 3·0-19·9). Most participants with prostate cancer had T1c disease and a Gleason score of 6 points (table 3). The distributions of age, PSA results, Gleason scores, and disease stage were well balanced across randomised groups (table 3) . The median follow-up is currently 8·6 years (IQR 7·1-10·4) and we have obtained vital status (primary outcome) info for 99% of patients, and secondary outcomes have been measured in 93%.
Of the 997 men who declined to be randomly assigned and expressed a preference for a particular treatment, 529 (53%) opted for active monitoring, 273 (27%) for radical prostatectomy, 133 (13%) for radiotherapy, 50 (5%) for brachytherapy, and 12 (1%) selected other treatments. 
Discussion
The ProtecT trial recruited and tested more than 82 000 community-based men aged 50-69 years. More than 8000 men had a PSA concentration of 3·0 μg/L or more, and of those, 87% received a biopsy, resulting in nearly 3000 men diagnosed with prostate cancer (4% of those recruited). Including eligible men recruited in the pilot study, 1643 (62%) of 2664 participants were randomly assigned to active monitoring, radical prostatectomy, or radiotherapy. In this initial report, median 8-year follow-up is more than 93% for all endpoints (99% for the primary outcome). The ProtecT trial was designed to address key issues in the management of clinically localised prostate cancer, specifi cally the comparative eff ectiveness and costeff ectiveness of the three conventional treatment modalities, including the trade-off between early diagnosis with PSA testing and the risks of over-detection and over-treatment. Trial design features that will enhance the robustness of the fi ndings include standardised diagnostic, treatment, and follow-up protocols; internal and external quality assurance processes; allocation concealment; high compliance with follow-up; extensive secondary outcomes; and an independent, masked primary endpoint committee. Randomisation was successful and baseline characteristics were evenly distributed across treatment groups. However, the study does have some limitations. The recruitment process was based on PSA testing, which is known to over-detect prostate cancer, and has the potential to be superseded by newer diagnostic modalities such as pre-biopsy imaging. Additionally, the long natural history of the disease means that the study will have taken more than 15 years to report, from fi rst patient participation in 1999 to the planned analysis of primary outcome after a median 10-year follow-up in November, 2015. Furthermore, during the past decade radical surgery has evolved with the introduction of robot-assisted and laparoscopic techniques, but few of these new approaches were undertaken in this trial. Other treatments have also changed: brachytherapy, dose escalation, and intensitymodulated radiotherapy are not being assessed in ProtecT, and active surveillance cohorts now tend to focus on men with a Gleason score of 6 points and use scheduled prostate biopsies-eg, PRIAS (Prostate Cancer Research International Active Surveillance). 29 Another limitation is that the lack of ethnic diversity in the study population might limit the applicability of the ProtecT fi ndings to non-white populations. Also, men younger than 50 years or older than 69 years were not eligible, nor Data are number (%) or median (range). *One person was aged 49 years when the primary care list was generated, but fi tted the stated inclusion criteria as per protocol. †One patient from the feasibility study had a serum PSA concentration of 20·9 μg/L at the specialist nurse visit; the concentration fell to 17·6 μg/L on repeat measurement and he became eligible for recruitment. Data are median (range) or number (%). *24 patients are classifi ed as non-randomised because they were part of the early study with randomisation only between radical treatments (not active monitoring). †One person was aged 49 years when the primary care list was generated, but fi tted the stated inclusion criteria as per protocol. ‡p value is a result of the comparison between white ethnic origin and all other ethic origins. §Based on resident area-based material and social deprivation scores using several indicators of income and living conditions-eg, percentage of social housing. were men with a PSA concentration of 20 μg/L or higher because they were likely to harbour non-localised cancer and an increased risk of lymph node metastasis, as shown by Joniau and colleagues. 30 Although we acknowledge that recent advances in imaging techniques would have improved staging in these patients, only 279 (0·3%) of 82 429 participants in our tested cohort had a PSA concentration of 20 μg/L or higher.
Additionally, the recruited population could be generally healthier than the overall population, as often occurs in screening trials, but this does not aff ect the compara tive eff ectiveness analyses of treat ments. 3, 5 Furthermore, UK statistics in 2008 suggested that prostate cancer mortality in the active monitoring group would be around 10% after 10 years-lower than expected at the trial outset. Therefore the mortality risk diff erence of 4·6%, upon which the original sample size was based, roughly corresponds to a hazard ratio of 0·54 in the revised calculation-a substantial benefi t of radical compared with conservative management. Should results from this trial support early active intervention, evidence will be needed that benefi ts are suffi ciently large to outweigh the well recognised complications of radical treatments.
The primary analysis will be highly informative for clinicians, patients, and decision makers because the trial has been designed to consider mortality, resource use, and quality-of-life outcomes. And, as with the other treatment trials, the fi ndings will continue to be of interest as the data mature over time.
The study's limitations need to be balanced against a number of strengths that ensure that the ProtecT trial will be of pivotal importance in establishing the comparative eff ectiveness of the three most frequently used treatment options in PSA-detected clinically localised prostate cancer. It is the largest ongoing randomised controlled trial of prostate cancer treatments worldwide, with standardised protocols for diagnosis, treatment, and follow-up and enabling an assessment of screening through the linked CAP trial. The core age group of the ProtecT trial is similar to that of other randomised control trials. High levels of generalisability are assured by embedding ProtecT within the CAP randomised control trial of population-based PSA testing involving about 1·5% of all UK men aged 50-69 years recruited from randomly selected primary care centres. Participants with intermediate and some high-risk disease features were included and will help to establish whether active monitoring protocols can off er an alternative to immediate radical intervention in these patients. The planned subgroup analyses of treatment eff ectiveness by stage and grade will investigate this aspect and assist comparison with SPCG-4 and PIVOT treatment trial patients. Furthermore, the assessment of a radiotherapy and neoadjuvant regimen will be relevant for patients with higher risk disease because good evidence already exists for endocrine therapy combined with radiotherapy for advanced disease. 31 ProtecT detected more prostate cancer in the fi rst round of testing than did the ERSPC and PLCO trials, probably because of ProtecT's lower PSA threshold combined with the minimum ten-core biopsy protocol in a population previously unexposed to routine PSA testing. The clinical characteristics of the participants' cancers in the ProtecT trial are similar to those of other unscreened populations. 32 Cancer was generally detected at a lower stage and grade in ProtecT participants than in a UK cohort of patients with clinically detected prostate cancer in the early 2000s. 33 However, this reduction in stage and grade would have been mitigated by the upward grade migration reported in Gleason scoring in NHS practice between 2000 and 2010. 34 Nevertheless, the mean proportion of UK men whose PSA concentration has been tested remains low by international standards at 6% (range 2-9) in primary care centres in the mid2000s. Compared with the PIVOT 6 and SPCG-4 7 treatment trials, ProtecT participants had the lowest PSA concentration, age, and included fewer higher stage cancers at the point of randomisation (table 5) . Randomisation of eligible participants was higher in ProtecT (62%) than in PIVOT (15%), and other similar trials did not complete recruitment (eg, START, SPIRIT). The acceptability of randomisation in the ProtecT trial was enhanced by integrated qualitative research. 35 Most notably, ProtecT participants received active monitoring, not watchful waiting as in PIVOT 6 and SPCG-4. 7 Current active surveillance protocols have more restrictive entry criteria and rely more on scheduled re-biopsy than in ProtecT, but ProtecT trial results will provide, to our knowledge, the fi rst randomised evidence for a monitoring strategy that includes the option of radical treatment (panel).
In 2016, the ProtecT trial will provide data for the comparative eff ectiveness and cost-eff ectiveness of active monitoring, radical prostatectomy, and radiotherapy in men diagnosed with localised prostate cancer after PSA testing with a median 10-year follow-up. These treatments are the major conventional options, and will be compared within an entirely PSA-tested cohort. The major fi ndings will provide key information needed to underpin the management of clinically localised prostate cancer, including the crucial trade-off between survival gains and potential harm caused by over-detection and unnecessary radical treatment in PSA-detected prostate cancer.
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